PF-Atlas › Drugs › Aberrant Basaloid Cell Elimination

Aberrant Basaloid Cell Elimination

Idiopathic Pulmonary Fibrosis · Target LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal source

Mechanism
Target LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal source
Development stage
Preclinical
Evidence level
Level 3 (Preclinical)
Developer
Novel

Overview

KRT17+/LAMB3+ basaloid cells drive fibrosis at active margins. Specific surface markers enable targeted elimination.

Explore related

Treatment profileTarget LAMB3+/KRT17+ aberrant cells — remove pro-fibrotic signal sourceAll trialsResearch
Medical disclaimer. This page summarizes research about Aberrant Basaloid Cell Elimination for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.